Cellectis S.A. (NASDAQ:CLLS – Get Rating) has received an average recommendation of “Hold” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $13.00.
A number of research analysts recently issued reports on the stock. The Goldman Sachs Group decreased their price target on shares of Cellectis from $3.00 to $2.00 and set a “sell” rating for the company in a research note on Tuesday, May 24th. Barclays lowered their target price on shares of Cellectis from $9.00 to $7.00 in a research note on Friday, May 13th. Robert W. Baird upgraded Cellectis from a “neutral” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, May 18th. They noted that the move was a valuation call. Finally, StockNews.com downgraded Cellectis from a “hold” rating to a “sell” rating in a report on Friday, June 10th.
Several hedge funds and other institutional investors have recently made changes to their positions in CLLS. BlackRock Inc. increased its position in Cellectis by 5.9% during the third quarter. BlackRock Inc. now owns 312,256 shares of the biotechnology company’s stock worth $3,937,000 after buying an additional 17,387 shares during the period. Millennium Management LLC raised its position in Cellectis by 180.9% in the 3rd quarter. Millennium Management LLC now owns 186,140 shares of the biotechnology company’s stock valued at $2,347,000 after purchasing an additional 119,872 shares during the last quarter. Jane Street Group LLC acquired a new stake in Cellectis during the 3rd quarter worth $2,212,000. Moors & Cabot Inc. purchased a new position in Cellectis during the 3rd quarter worth $287,000. Finally, Exchange Traded Concepts LLC increased its stake in Cellectis by 47.4% in the fourth quarter. Exchange Traded Concepts LLC now owns 347,174 shares of the biotechnology company’s stock valued at $2,819,000 after purchasing an additional 111,591 shares during the period. 40.55% of the stock is owned by hedge funds and other institutional investors.
Cellectis (NASDAQ:CLLS – Get Rating) last issued its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.08). The company had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $22.85 million. Cellectis had a negative return on equity of 53.48% and a negative net margin of 312.64%. Sell-side analysts predict that Cellectis will post -2.31 earnings per share for the current year.
About Cellectis (Get Rating)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on Cellectis (CLLS)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.